TG Therapeutics, Inc. TGTX
Set alert
59.95 USD -1.23 -2.01%
At close · Nov 2
59.93 -0.02 -0.03%
After hours · Nov 2, 6:56 PM ET
59.59 Day range 63.60
26.76 52-week range 63.60
- YTD
- +101.11%
- 1 year
- +72.37%
- Open
- 61.01
- Prev close
- 61.18
- Mkt cap
- 9.18B
- Vol
- 2.58M
- Avg vol
- 1.87M
- EPS
- 2.75
- P/E
- 21.80
- Div yield
- 0.00%
More statistics
- Low
- 59.59
- High
- 63.60
- Forward P/E
- 22.14
- Beta
- 1.81
- Short ratio
- 16.22
- Inst. own
- 74.69%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 55.33
- 200-d avg
- 43.81
- 1y target
- 69.71
MAX chart
Events in this range
- Aug 4, 2025Earnings: 0.17; estimate 0.32; surprise -46.87%
- Nov 3, 2025Earnings: 2.43; estimate 0.24; surprise 912.5%
- May 6, 2026Earnings: 0.14; estimate 0.23; surprise -39.13%
- Jul 6, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Jul 7, 2026Rating: B of A Securities · Underperform → Underperform
- Aug 3, 2026Earnings: 0.05; estimate 0.3057; surprise -83.64%
- Aug 7, 2026Rating: JP Morgan · Overweight → Overweight
- Sep 1, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 0.3668; surprise —%
Signals (56)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Sep 1, 2026 | 2 months ago |
| MACD: Buy Signal | Jun 1, 2026 | 5 months ago |
| RSI: Overbought | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | Mar 1, 2026 | 8 months ago |
| MACD: Sell Signal | Nov 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| RSI: Overbought | Apr 1, 2025 | 1 year ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 1, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 1, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| SMA: Bearish | Nov 1, 2021 | 5 years ago |
| MACD: Sell Signal | Aug 1, 2021 | 5 years ago |
| SMA: Bearish | May 1, 2021 | 5 years ago |
| RSI: Overbought | Aug 1, 2020 | 6 years ago |
| SMA: Bullish | Dec 1, 2019 | 6 years ago |
| MACD: Buy Signal | Nov 1, 2019 | 7 years ago |
| SMA: Bullish | Oct 1, 2019 | 7 years ago |
| SMA: Bearish | Aug 1, 2019 | 7 years ago |
| SMA: Bullish | Jun 1, 2019 | 7 years ago |
| SMA: Bearish | May 1, 2019 | 7 years ago |
| SMA: Bullish | Mar 1, 2019 | 7 years ago |
| SMA: Bearish | Sep 1, 2018 | 8 years ago |
| SMA: Bearish | Sep 1, 2018 | 8 years ago |
| MACD: Sell Signal | Sep 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bullish | Jan 1, 2018 | 8 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bearish | Oct 1, 2017 | 9 years ago |
| SMA: Bullish | Jul 1, 2017 | 9 years ago |
| SMA: Bearish | Jun 1, 2017 | 9 years ago |
| SMA: Bullish | Mar 1, 2017 | 9 years ago |
| SMA: Bullish | Mar 1, 2017 | 9 years ago |
| MACD: Buy Signal | Mar 1, 2017 | 9 years ago |
| SMA: Bearish | Jan 1, 2016 | 10 years ago |
| MACD: Sell Signal | Jan 1, 2016 | 10 years ago |
| SMA: Bearish | Aug 1, 2015 | 11 years ago |
| SMA: Bullish | May 1, 2014 | 12 years ago |
| SMA: Bearish | Apr 1, 2014 | 12 years ago |
| SMA: Bullish | Jan 1, 2014 | 12 years ago |
| SMA: Bullish | Jan 1, 2014 | 12 years ago |
| SMA: Bearish | Sep 1, 2013 | 13 years ago |
| SMA: Bullish | Mar 1, 2013 | 13 years ago |
| SMA: Bearish | Aug 1, 2012 | 14 years ago |
| SMA: Bullish | May 1, 2012 | 14 years ago |
Key statistics
- Market cap
- 9.18B
- Enterprise value
- 8.88B
- Trailing P/E
- 21.80
- Forward P/E
- 22.14
- PEG ratio
- 1.61
- Price / sales
- 11.48
- Price / book
- 14.08
- EPS (TTM)
- 2.75
- Beta
- 1.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 55.22%
- Revenue (TTM)
- 799.54M
- Revenue growth
- 70.30%
- Free cash flow
- 59.13M
- Total cash
- 552.25M
- Total debt
- 754.44M
- Return on equity
- 100.28%
- Shares outstanding
- 153.07M
- Short % of float
- 27.94%
- 50-day average
- 55.33
- 200-day average
- 43.81
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 69.71 +16.3% upside
Now 59.95
- Target (low)
- 21.00
- Target (mean)
- 69.71
- Target (high)
- 86.00
Ratings (0m) 8 7 buy · 0 hold · 1 sell
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell1
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.2575.
Financials — quick view
TGTX Revenue — quarterly 240.34M
TGTX Net income — quarterly 7.78M
TGTX EPS — quarterly 0.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.3668 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.3057 | 0.05 | -0.26 | -83.64% |
| May 6, 2026 | Mar 31, 2026 | 0.23 | 0.14 | -0.09 | -39.13% |
| Feb 26, 2026 | Dec 31, 2025 | 0.35 | 0.14 | -0.21 | -60.00% |
| Nov 3, 2025 | Sep 30, 2025 | 0.24 | 2.43 | +2.19 | +912.50% |
| Aug 4, 2025 | Jun 30, 2025 | 0.32 | 0.17 | -0.15 | -46.87% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 27, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 7, 2026 | B of A Securities | main | Underperform | Underperform |
| Jul 6, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tgtherapeutics.com
News
- TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
- GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth
- TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- TG Therapeutics' Initial Data From Its Phase 1 Trial Of Azercabtagene Zapreleucel In Patients With Progressive Multiple Sclerosis Demonstrates 89% Of Evaluable Participants Had Stable Or Improved Disability Scores At Day 90
- TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
- TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
- TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
- TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
- TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
Your note
Sign in to keep a note on TGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARNEY LAURENCE NEIL | Director | Sale | Sep 9, 2026 | 168,640 |
| ECHELARD YANN | Director | Sale | Nov 23, 2025 | 223,816 |
| HOBERMAN KENNETH | Director | Stock Award(Grant) | Jun 11, 2025 | 279,653 |
| HUME DANIEL | Director | Stock Award(Grant) | Jun 11, 2025 | 192,748 |
| LONIAL SAGAR | Director | Sale | Sep 10, 2025 | 94,061 |
| POWER SEAN A | Chief Financial Officer | Stock Award(Grant) | Jan 7, 2026 | 798,111 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.41% | 22,050,045 | 1.32B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.20% | 7,963,266 | 477.40M | Jun 29, 2026 |
| State Street Corporation | 5.09% | 7,786,471 | 466.80M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.02% | 6,149,403 | 368.66M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.38% | 3,642,216 | 218.35M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 2.22% | 3,400,808 | 203.88M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.52% | 8,449,942 | 506.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 4,377,027 | 262.40M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 3,765,888 | 225.76M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.06% | 3,160,785 | 189.49M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.77% | 2,703,952 | 162.10M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.19% | 1,820,899 | 109.16M | Jun 29, 2026 |